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Reply
To the Editor:
A prompt therapeutic response to corticosteroids is 
one of the characteristic features of PMR. However, due to the 
age of the patient population affected, steroid side effects are 
likely. Minimizing the steroid dose remains an attractive goal 
in the management of these patients. Cytokine measurements 
might be suitable for monitoring disease activity and adjusting 
the steroid therapy appropriately.
Tellus et al have addressed the question of whether 
IL-6 , IL-8 , and TNFtv concentrations in the blood represent 
sensitive tools for assessing disease activity in patients with 
PMR. In their study, 4 patients with established PMR were 
monitored for different parameters indicative of acute-phase 
responses. The authors found that despite marked elevations 
in the HSR and CRP level, serum levels of IL-6 , IL-8 , or TNFa 
were not increased. Normal levels of IL-6 were defined as <20 
pg/mi. They concluded that both accurate timing of the sample 
collection and highly sensitive cytokine assays are necessary to 
reliably monitor these mediators in the blood.
We and others have previously reported that elevated 
plasma levels of IL -6 is a consistent finding in patients with 
untreated or partially treated PMR and GCA (1,2). Peripheral 
blood monocytes are consti tu lively activated in both diseases 
and represent the likely source of the circulating IL-6 (3). Our 
original observation that plasma IL-6 levels correlated expli­
citly well with symptoms in patients with PMR prompted us to 
monitor standard clinical and laboratory parameters and 
plasma IL-6 concentrations in a prospective study.
Thus far, we have enrolled 24 patients with PMR and 
14 patients with biopsy-proven GCA. We have used a com­
mercial ELISA that has a sensitivity of <1 pg/mi to determine 
IL -6 levels (R & D, Minneapolis, MN). Plasma IL-6 levels in 
normal controls are 1.3 ± 1.6 pg/ml (mean ± SD). Thirty-eight 
percent of patients with PMR had IL-6 concentrations above
20 pg/ml at the initial presentation. In 79% of patients, 
pretreatment IL -6 levels were higher than 5 pg/ml. In general, 
patients with lower IL-6 levels also had a lower ESR. However, 
we agree with the observation of Tellus et al that there is not 
a linear correlation between IL-6 levels and the ESR. In the 
longitudinal studies, increases in plasma IL-6 levels correlated 
with flares of PMR and increased requirements for steroids. 
Interestingly, both IL-6 elevations and steroid dose increases 
necessary to control clinical disease could be subtle.
One intriguing observation from these studies is that 
heterogeneity exists for IL-6 induction in the patient popula­
tion. Some patients have highly elevated plasma concentra­
tions of IL-6 , but a small fraction of patients appears not to 
produce increased amounts of IL-6 . In patients with PMR, this 
heterogeneity could reflect a diversity of disease processes 
presenting with a PMR-like syndrome. However, we have seen 
a similar phenomenon in patients with biopsy-proven GCA. 
We have therefore begun to explore the possibility that genetic 
heterogeneity is responsible for the differences in IL -6 induc­
tion. The distinct geographic distribution of PMR and GCA, 
with a marked preference for individuals of Northern Euro­
pean origin, is likely a surrogate for genetic risk determinants 
clustering in some ethnic populations. The regulation of IL-6 
production may be related to such a genetic susceptibility 
factor. Comparison of patients from different geographic 
regions and of different ethnic origin will be extremely helpful 
in unraveling genetic components in PMR and GCA.
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Analysis of anti-Ul RNA antibodies in patients with 
connective tissue diseases: comment on the article by 
Hoffman et al
To the Editor:
We read with interest the article by Hoffman and 
coworkers, in which they report a correlation between the 
presence of anti-Ul RNA antibodies with anti-70K and anti-A 
polypeptide antibodies, and the immunogenetic distinction 
between the anti-Ul RNA positive connective tissue disease 
(CTD) patient group with the anti-Ul RNA negative patient 
group (1). Furthermore, Hoffman et al found that the anti-Ul 
RNP positive, anti-Ul RNA negative group consisted of 
patients with various symptoms of mild mixed connective tissue 
disease (MCTD) and systemic lupus erythematosus (SLE), 
while the anti-Ul RNP, anti-Ul RNA positive group com-
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prised patients with more typical MCTD features. According 
to the authors, these findings indicate that the presence of 
anti-Ul RNA antibodies may be a specific marker for MCTD.
This indication needs to be further examined since the 
concept of MCTD as a separate disease entity has been 
challenged (2), and since the majority of patients with MCTD 
will eventually fulfill well-established classification criteria for 
SLE, systemic sclerosis (SSc), rheumatoid arthritis (RA), or 
combinations of these diseases (3). The authors should have 
shown how many anti-Ul RNA positive patients in their study 
fulfilled classification criteria for CTDs such as SLE, SSc, RA, 
Sjogren’s syndrome, or polymyositis/dermatomyositis. More­
over, in larger groups of anti-Ul RNP positive patients with a 
well-established CTD, the presence of anti-Ul RNA antibod­
ies should be examined. Without these analyses, no judgment 
about the specificity of anti-Ul RNA antibodies can be made.
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Reply
To the Editor:
We recognize that disease classification for patients 
with MCTD is an area of controversy among some investiga­
tors who would prefer to classify MCTD as SLE or SSc, or 
simply rename MCTD as “undifferentiated connective tissue 
disease.” We have recently reviewed this controversy and have 
discussed the problems that are encountered in all disease 
classification schemes, wherein the etiology of a disease is 
unknown and the clinical manifestations are pleomorphic and 
overlap with other diseases (1). Briefly, it is important to recall 
that a single clinical syndrome (e.g., polyarthritis) may have 
many etiologies, and a disease with a single etiology (e.g., 
Lyme disease) may cause many different clinical syndromes. 
Until the precise etiology of each of the entities (i.e., MCTD, 
SLE, and SSc) is known, controversy will remain. Based on its 
distinctive clinical, serologic, and, more recently, immunoge- 
netic characteristics, we believe that recognition of MCTD
purpose for research, as well as for 
treatment and prognosis (1).
Contrary to the statement of van den Hoogen et al, it 
is not definite that the MCTD in the majority of patients will 
progress to fulfill well-established classification criteria for 
other rheumatic diseases (1-3). Furthermore, only 2 published
serve a
reports have examined this question among relatively small 
numbers of anti-Ul RNA positive patients (4,5), and clearly, 
more study is needed before any final conclusions can be 
reached.
A large and expanding body of data support our 
position that disease classification by specific autoantibodies 
and HLA genotypes identifies distinct disease groups in pa­
tients more precisely than can be accomplished using previous 
serologic or clinical classification schemes, either alone or in 
combination (6). We have recently reviewed the relationship 
between autoantibodies, immunogenetic markers, and disease 
classification (6).
We disagree with van den Hoogen et al that stratifica­
tion of patients by clinical disease classification criteria rather 
than by serologic criteria, such as the presence of anticentro­
mere antibodies, anti-SS-A/Ro and anti-SS-B/La antibodies, 
anti-double-stranded DNA (dsDNA) antibodies, or anti-RNP 
antibodies, would have enhanced our study. We intentionally 
classified patients based solely upon serologic findings in an 
attempt to avoid ambiguity and inadvertent bias in our selec­
tion criteria. We would note for the readers’ interest that the 
patients who were reported (4) to have anticentromere anti­
bodies had SSc, those with anti-SS-A/Ro or anti-SS-B/La had
«
Sjogren’s syndrome or SLE, and those with anti-dsDNA anti­
bodies had SLE.
Finally, we agree that collaborative, multicenter, inter­
national studies using large numbers of well-characterized 
patients should be performed, and might provide additional 
information on the nature of patients possessing anti-Ul RNA 
antibodies. Only by moving forward in cooperation will these 
questions be answered.
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